Resona Asset Management Co. Ltd. decreased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 238,290 shares of the company’s stock after selling 2,912 shares during the period. Eli Lilly and Company accounts for about 1.3% of Resona Asset Management Co. Ltd.’s investment portfolio, making the stock its 13th biggest position. Resona Asset Management Co. Ltd.’s holdings in Eli Lilly and Company were worth $277,178,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of LLY. Torren Management LLC raised its position in Eli Lilly and Company by 357.1% during the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after purchasing an additional 25 shares in the last quarter. Foresight Capital Management Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $49,000. Caitlin John LLC purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $64,000. IMG Wealth Management Inc. lifted its position in shares of Eli Lilly and Company by 500.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock worth $72,000 after purchasing an additional 50 shares during the period. Finally, John Boyer Inc. bought a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $72,000. Institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Trading Down 0.3%
Shares of Eli Lilly and Company stock opened at $1,346.40 on Friday. The firm’s 50 day simple moving average is $1,268.06 and its two-hundred day simple moving average is $1,119.25. The firm has a market capitalization of $1.27 trillion, a price-to-earnings ratio of 43.70, a PEG ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,475.25. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $7.02 earnings per share. Analysts predict that Eli Lilly and Company will post 35.72 EPS for the current year.
Eli Lilly and Company Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.
Insider Transactions at Eli Lilly and Company
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on LLY. Sanford C. Bernstein reiterated an “outperform” rating and issued a $1,450.00 price target on shares of Eli Lilly and Company in a report on Monday, October 26th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. HSBC lifted their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Finally, Guggenheim increased their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,422.00.
Get Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company News Summary
Here’s some of the latest news about LLY:
- Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, potentially broadening the drug’s use and commercial opportunity. Article: Health Canada approves Lilly’s Mounjaro
- Positive Sentiment: Lilly is expanding its oncology research through the acquisition of Calytrix Bio and a multi-target collaboration with Stipple Bio. The deals add programs and research capabilities, though their financial impact will depend on development progress. Article: Eli Lilly expands its oncology research platform
- Negative Sentiment: Healthcare ETFs reportedly sold Lilly shares, including $17.4 million from IYH and $42.3 million from XLV. These sales may add some market pressure, though they appear to be fund-position changes rather than a company-specific development. Article: IYH sells Eli Lilly shares
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
See Also
- Five stocks we like better than Eli Lilly and Company
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
